Cerus Corporation Aktie News

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) gab heute bekannt, dass es auf der Jahrestagung 2026 der Association for the Advancement of Blood and Biotherapies (AABB), die vom 17. bis 19. Oktober in Atlanta, Georgia, stattfindet, einen Branchenworkshop zur Implementierung und zu Erfahrungen aus der Praxis mit INTERCEPT Platelets und INTERCEPT Fibrinogen Complex, oder IFC*,...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) gab heute die Finanzergebnisse für das zum 30. Juni 2026 endende zweite Quartal 2026 bekannt und lieferte ein Geschäfts-Update. „In diesem Quartal haben wir bedeutende Fortschritte gemacht, um den Patientenzugang zu sichereren Blutkomponenten weltweit auszubauen“, sagte Vivek Jayaraman, Präsident und Chief Executive Officer von ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approxi...

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' p...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud t...